27 March 2018 - PHARMAC is seeking feedback on a proposal to list aflibercept (Eylea) and rivaroxaban (Xarelto) through a provisional agreement with Bayer. 

PHARMAC is also seeking feedback on a proposal to amend the current hospital restrictions for ranibizumab.

This proposal takes into account feedback received from a previous consultation issued in September 2016 on a request for proposals (RFP) for anti-VEGF agents, and PHARMAC’s subsequent December 2016 decision to terminate the RFP process.

PHARMAC is proposing to list:

• aflibercept (Eylea) 40 mg per ml, 0.1 ml vials, from 1 June 2018, in Section B and in Part II of Section H of the Pharmaceutical Schedule, with restrictions;
  
• rivaroxaban (Xarelto) 10 mg, 15 mg, and 20 mg tablets, from 1 August 2018, in Section B and in Part II of Section H of the Pharmaceutical Schedule, without restrictions (open list).
  

Read PHARMAC Consultation